Celestia S. Higano
Fred Hutchinson Cancer Research Center
465 Papers
3.4K Citations
Celestia S. Higano is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 78, co-authored 423 publications. Previous affiliations of Celestia S. Higano include United States Department of Veterans Affairs & Ohio State University.
Chat about Author
Papers
Guidelines for Sexual Health Care for Prostate Cancer Patients: Recommendations of an International Panel.
Daniela Wittmann,Akanksha Mehta,Eilis McCaughan,Martha M. Faraday,Ashley Duby,Andrew Matthew,Luca Incrocci,Arthur L. Burnett,Christian J. Nelson,Stacy Elliott,Bridget F. Koontz,Sharon L. Bober,Deborah McLeod,Paolo Capogrosso,Tet Yap,Celestia S. Higano,Stacy Loeb,Emily Capellari,Michael Glode,Heather Honoré Goltz,Doug Howell,Michael Kirby,Nelson E. Bennett,Landon Trost,Phillip Odiyo Ouma,Run-Zhi Wang,Carolyn A. Salter,Ted A. Skolarus,John A. McPhail,Susan McPhail,J. Brandon,Laurel L. Northouse,Kellie Paich,Craig Evan Pollack,Jennifer Shifferd,Kim Erickson,John P. Mulhall +36 more
TL;DR: Guidelines for sexual health care for patients with prostate cancer were developed, based on available evidence and the expertise of the international panel as mentioned in this paper , which included international expert researchers and clinicians, and a guideline methodologist.
4
Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Daniel J. George,Cora N. Sternberg,A. Oliver Sartor,Fred Saad,Bertrand F. Tombal,Kurt Miller,Jan Kalinovsky,XiaoLong Jiao,Krishna Tangirala,Celestia S. Higano +9 more
TL;DR: Clinical outcomes in pts with mCRPC who received concurrent or layered Ra-223 + Abi treatment and prior therapies, and clinical outcomes including skeletal-related events (SREs) and overall survival (OS) are evaluated.
4
Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer. A Southwest Oncology Group Study.
Carolyn Collins,Celestia S. Higano,Robert B. Livingston,Brian R. Griffin,Michael D. Keppen,Thomas P. Miller +5 more
TL;DR: This regimen produced significant myelosuppression, with 5 neutropenic deaths occuring in the 38 patients evaluable for toxicity, and did not result in a CR rate or survival advantage that would suggest its superiority over standard regimens for small-cell lung cancer.
4
Cooperative group trials-Southwest Oncology Group (SWOG) innovations in advanced prostate cancer
Tanya B. Dorff,Catherine M. Tangen,E. David Crawford,Daniel P. Petrylak,Celestia S. Higano,Derek Raghavan,David I. Quinn,Nicholas J. Vogelzang,Ian M. Thompson,Maha Hussain +9 more
TL;DR: Findings from recent SWOG clinical trials for advanced prostate cancer are highlighted, emphasizing the clinical impact and future applications of the data.
4